A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy
Fiche du document
7 septembre 2018
- handle: 10670/1.j8ix7x
- doi: 10.1016/j.sleep.2014.10.004
Mots-clés
Attention Cataplexy Efficacy Excessive daytime sleepiness Narcolepsy Open-label Patient-reported outcomes Safety Sleep quality Sodium oxybateSujets proches
Hydroxybutyrate Sodium oxybate Oxybate sodium Gamma hydrate Sodium gamma-hydroxybutyrate GHB (Drug) Sodium oxybutyrate Semiology (Medicine) Diseases--Symptoms Symptomatology Signs, Clinical Clinical signs Semiology Symptomology Signs and symptoms Disease symptomsCiter ce document
Mortimer Mamelak et al., « A 12-week open-label, multicenter study evaluating the safety and patient-reported efficacy of sodium oxybate in patients with narcolepsy and cataplexy », Papyrus : le dépôt institutionnel de l'Université de Montréal, ID : 10.1016/j.sleep.2014.10.004
Métriques
Partage / Export
Résumé
Objective: This study aimed to evaluate safety and efficacy of sodium oxybate (SXB) titrated to effect. Methods: SXB-naive patients who had participated in a randomized SXB clinical trial and had not been titrated to adequate clinical effect were initiated on open-label SXB at 4.5 g/night and titrated in 1.5-g increments to 6, 7.5, or 9 g/night or down to 3 g/night, based on individual clinical response. Treatment was 12 weeks; safety was the primary outcome. Efficacy was evaluated using the Narcolepsy Symptom Assessment Questionnaire (NSAQ), a five-point scale (“much improved” to “much worse”) that assessed changes from baseline in specific symptoms. Response was defined as “much improved” or “somewhat improved” overall at weeks 6 and 12. Results: Of 202 patients, 171 (85%) completed treatment; final doses were 3 g (n = 5), 4.5 g (n = 29), 6 g (n = 80), 7.5 g (n = 66), and 9 g (n = 22). Adverse events (AEs) were reported in 114 patients (56%), serious AEs in five (2%). The most common AEs were nausea (10%), headache (7%), and dizziness (5%). Response rate was 92% at week 6 and 90% at week 12; most patients reported improvements in all individual symptoms. Overall, 60% of patients rated their symptoms at 12weeks as “much improved,” and this improvement was dose dependent. Conclusions: The SXB safety profile was consistent with parent trials. Ninety percent of patients reported improvements as measured by the NSAQ.